PubMed Health⌕ Search

Biomedical subjects

Alok Maheshwari

Publications and source records attributed to Alok Maheshwari.

11 recordsLinked to original sources
PubMed2005

Impact of frame selection on quantitative coronary angiographic analysis after coronary stenting.

This study examined the impact of frame selection on the results of quantitative coronary angiographic analysis (QCA). Thirty-nine patients who had stent implantation and a follow-up angiogram 5-7 months later were studied using the CMS Medis QCA system. The acute and follow-up films (n = 39) were read in three different ways to assess the impact of frame selection: frame chosen making the stent appear least narrowed (best); frame chosen making the stent appear most narrowed (worst); and measurement from the mean value from three consecutive end-diastolic frames (core). We measured the mean percent diameter stenosis immediately postintervention and at follow-up, the binary restenosis rate, and the late lumen loss (mm). There was a statistically significant difference in all of these variables when comparing the three methods of frame selection (best vs. worst, P values < 0.001; best or worst vs. core, P values < 0.01). This study demonstrates a marked variability in the results obtained using QCA to measure the acute and late coronary stent outcomes when operators have the ability to select which frame to analyze (frame bias).

Analysis of Variance↗
PubMed2004

Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.

BACKGROUND: Mortality benefit from implantable cardioverter defibrillator (ICD) therapy in ischemic cardiomyopathy (ICM) with non-sustained ventricular tachycardia (NS-VT) and inducible VT is well defined. Although NS-VT may suggest an increased risk of sudden cardiac death (SCD) in non-ischemic cardiomyopathy (NICM), the role of ICD therapy is unclear. This retrospective study compares follow-up data in these two groups after ICD implantation. METHODS: 153 consecutive patients with ICD implantation for NS-VT were analyzed. ICM patients received an ICD if they had inducible VT at electrophysiology study (EPS). NICM patients did not routinely undergo EPS before ICD implantation. RESULTS: There were 48 patients (33 males) in NICM group and 105 patients (89 males) in the ICM group. Baseline characteristics including mean ejection fraction (EF), distribution in various New York Heart Association (NYHA) classes, and the mean duration of follow up in the two groups were similar. 50% of the patients in the NICM group and 36% in the ICM group received appropriate therapies (p = 0.106). The mean number of appropriate therapies in the two groups were similar (23.3 +/- 56.7 and 22.5 +/- 59.5 respectively, p = NS). The percentage of patients with inappropriate therapies in the two groups were 27% and 23% respectively (p = NS). Patients in the NICM group received appropriate ICD discharges at a greater rate (p = 0.02). CONCLUSION: Patients undergoing ICD implantation for NICM and NS-VT receive appropriate ICD therapy at a greater rate than those implanted for ICM, NS-VT, and a positive EPS. Although these data do not prove survival benefit in NICM, they suggest a beneficial effect.

Adult↗
PubMed2004

Current applications for nicardipine in invasive and interventional cardiology.

Interventional coronary procedures, such as rotational atherectomy and coronary artery bypass graft (CABG) stenting, are associated with a risk of postoperative vasoconstriction, which can lead to sequelae that produce morbidity and even death. Vasodilators, such as calcium channel blockers, sodium nitroprusside and adenosine, are often administered to prevent or reverse these sequelae, and have proven effective for this purpose. The injectable dihydropyridine calcium channel blocker, nicardipine, has several unique properties that make it an effective option for preventing and/or reversing microvascular or conductance vessel vasoconstriction. In this review, we describe the evidence-based uses of nicardipine injection in interventional cardiology and cardiac catheterization procedures. In comparison to other calcium channel blockers, nicardipine injection appears to be potentially safer, easier to administer and capable of producing a more predictable response. This drug has potential advantages in preventing or reversing the no-reflow phenomenon that sometimes occurs after interventions in coronary bypass grafts. Nicardipine may also be effective when administered in a flush solution with other drugs during rotational atherectomy and clot debulking with or without distal protection devices. It also can control the hypertension that occurs after sternotomy and cardiac surgery, and in the cardiac catheterization laboratory. In summary, the dihydropyridine calcium channel blocker, nicardipine, has a wide range of useful applications during cardiovascular interventions.

Atherectomy, Coronary↗
PubMed2002

Prehospital ACLS--does it work?

Cardiac disease is the most common cause of death in the United States, and sudden cardiac arrest frequently claims the lives of men and women during their most productive years. It is believed that much better survival rates can be achieved for victims of cardiac arrest through optimizing the "chain of survival" as described by the American Heart Association. The relative and incremental benefit of full prehospital ACLS over basic life support and defibrillation is unproven, however. This is an important issue in this era of cost containment. Some of the ongoing studies including the OPALS study may clarify the cost effectiveness and relative efficacy of rapid defibrillation and full ACLS programs for victims of prehospital cardiac arrest [6].

Advanced Cardiac Life Support↗
PubMed2002

A novel catheter design for laser photocoagulation of the myocardium to ablate ventricular tachycardia.

Nd:YAG laser energy has been proposed as an alternative to radiofrequency energy for ablation of ventricular tachycardia (VT) associated with coronary artery disease (CAD) in an effort to increase lesion size and success rates. However, issues of catheter design to maintain flexibility and ensure adequate tissue contact have hindered development of laser catheters. We developed and tested a prototype 8 Fr. steerable catheter with a flexible and extendible tip (designed to ensure tissue contact and efficient ventricular mapping), which projects the laser beam through a side port containing a lens-tipped optical fiber that rests against the endocardial surface. The catheter has a channel for simultaneous saline irrigation to displace the interceding blood and discharge a laser beam between two electrodes for bipolar mapping and a thermocouple for temperature monitoring. The catheter was tested on bench top using the epicardial surface of freshly slaughtered bovine hearts and in vivo using six anaesthetized closed-chest sheep. In vitro experiments demonstrated that lesion size increased linearly with applied power up to 40 watts. When compared to radio frequency, laser energy penetrated more deeply into the myocardium. In the in vivo studies, using increasing powers of up to 40 watts for application times of 60 to 120 seconds created circular or elliptical lesions with surface dimensions up to 12 mm x 12 mm and depth of 9 mm (full LV wall thickness with a mean lesion diameter of 9.9 +/- 5.2 mm and depth 5.8 +/- 3.2 mm). Most lesions, 16 total in both right and left ventricular walls were transmural or near transmural in thickness. Lesions demonstrated coagulation necrosis with smooth well-demarcated borders. No animal suffered cardiac perforation, hypotension, hemopericardium, damage to cardiac valves, or cavitation effect from any of the ablations. Runs of VT were seen during energy application at the highest laser outputs in two animals. In conclusion, this catheter design provides effective endocardial delivery of laser energy and is capable of creating transmural or nearly transmural lesions in vivo and in vitro, thereby potentially increasing the efficiency of VT ablation in CAD patients.

Animals↗
PubMed2002

Adenosine induced ventricular fibrillation in Wolff-Parkinson-White syndrome.

VF was observed in four patients (group A) with preexcited AF presenting to the emergency department who had been given 12 mg of adenosine. These patients were resuscitated and underwent electrophysiological study and catheter ablation of the accessory pathway (AP). In a control (group B) of five patients with manifest AP, sustained AF was induced by rapid atrial pacing during electrophysiological study and 12 mg of adenosine was administered. The ECG and electrophysiologic features in the two groups were compared. All patients had a single manifest AP. In group A, three patients had a left free-wall AP and one patient had a posteroseptal AP, while in the control group all had left free-wall APs. The antegrade AP effective refractory period (ERP) in groups A and B was 227 +/- 29 and 289 +/- 37 ms, respectively (P < 0.05). The atrial ERP was 210 +/- 17 versus 219 +/- 21 ms, respectively, in groups A and B (P > 0.05). The shortest R-R interval during AF in group A was 246 +/- 51 ms and 301 +/- 60 ms in group B (P value < 0.05). After adenosine, no patient in group B developed VF. Adenosine may cause VF when administered during preexcited AF. This phenomenon is seen in patients having APs with short refractory periods.

Adenosine↗
PubMed2002

Primary radiofrequency ablation for incessant idiopathic ventricular tachycardia.

Fascicular VT and RVOT tachycardia are sometimes difficult to induce by programmed electrical stimulation (PES), despite pharmacologic provocation. In such instances, catheter mapping is hampered and efficacy of catheter ablation is difficult to judge. The study included nine patients who presented with incessant idiopathic VT and were directly taken to the electrophysiological laboratory for RF ablation. During the same period, elective ablation was performed on 108 patients with idiopathic VT. The success rate, procedural and fluoroscopy times number of energies, and the peak temperature were evaluated and compared. Of the nine patients, seven had incessant fascicular VT and two had RVOT tachycardia. The mean VT cycle length was 356 +/- 32 ms and the earliest endocardial activation time during VT was 23.6 +/- 6 ms relative to surface QRS complexes. A fascicular potential was not seen in three of the seven patients with fascicular VT. The mean procedural time was 71 +/- 32 minutes and 144 +/- 40 minutes (P = 0.023) while the fluoroscopy time was 14.6 +/- 4.6 minutes and 30 +/- 16 minutes (P < 0.001), respectively, in the primary ablation and elective groups. The total number of RF energies delivered was 2.0 +/- 1.3 versus 7.4 +/- 5.6 (P = 0.07), respectively. The significantly increased procedural time during elective ablation was largely due to time spent in fascicular VT induction. All patients in the primary ablation group were successfully ablated and none had a recurrence. Primary ablation is a safe and effective option in patients with incessant idiopathic VT. Moreover, in fascicular VT, it is superior to elective ablation in terms of success, fluoroscopy and procedural times.

Adolescent↗
PubMedDate not supplied

Effect of weight loss on QT dispersion in obesity.

BACKGROUND: Sudden cardiac death in patients on a liquid protein diet has been suggested to be related to repolarization abnormalities. Although increased QT dispersion is also associated with sudden cardiac death, it has not been examined in the setting of weight loss using liquid protein diet. METHODS AND RESULTS: Sixty-three patients (mean age 42 years, 18 men) with a mean initial weight of 116 kg were randomly chosen from patients who had completed 26 weeks of liquid protein diet therapy. QT, corrected QT interval, QT dispersion and corrected QT dispersion were measured blindly along with serum albumin and electrolytes at the beginning and end of 26 weeks of liquid protein diet therapy. In 57 patients (89.5%) (group 1), QT dispersion shortened after weight loss while it was prolonged in 6 patients (10.5%) (group 2). The mean weight loss (group 1: 115+/-21 to 91+/-16 kg; group 2: 122+/-21 to 98+/-13 kg), and serum albumin and electrolyte levels before weight loss were the same in both groups. The decrease in QT dispersion in group 1 was due to increase in the minimum QT interval (350+/-22 v. 375+/-21 mis, p<0.01) after weight loss. However, the QT dispersion increase in group 2 was due to prolongation of the maximum QT interval (402+/-27 v. 441+/-19 ms, p<0.05) after weight loss. This suggests that shortening of the minimum QT interval causes the increased QT dispersion in obesity. Half the patients in group 2 showed a drop in the serum albumin level and 2 patients had an abnormally high phosphorous level at the end of the treatment. CONCLUSIONS: QT dispersion shortens in most patients (89.5%) using liquid protein diet for weight loss. However, increase of QT dispersion is seen in 10.5% of patients. The cause of increased QT dispersion in obesity (before weight loss) differs from that in patients after weight-loss using liquid protein diet. QT dispersion changes observed in this study may explain the risk of sudden cardiac death in these patients.

Adult↗
PubMedDate not supplied

Catheter ablation of atrial tachycardia using a real-time position management mapping system.

Catheter ablation for atrial tachycardia is limited by its low success rate and prolonged procedure time because of difficulties in mapping the site of the tachycardia. A new three-dimensional mapping system, the Cardiac Pathways mapping system, using an ultrasound transducer, has recently become available. We report a case of focal atrial tachycardia ablation with this system.

Catheter Ablation↗